Leveraging computer-aided drug design, we will explore the potential of designing novel therapeutic agents that could modulate the p21-CCND1-CDK4 axis, offering new and exciting avenues for targeted therapy in NSCLC. This evidence concerns the gene CCND1 and non-small cell lung carcinoma.